General ENT News

ENT

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Manthey KC et al. – Loss of RPA2 hyperphosphorylation occurs in HNSCC cells and may be a marker of cellular sensitivities to cisplatin and etoposide in HNSCC.

Related Articles

Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
New England Journal of Medicine, 10/22/09    Relevance Score: 97%

Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: Relevance of age and dose as risk factors
European Journal of Cancer, 10/23/09    Relevance Score: 91%

Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma
American Journal of Clinical Oncology, 10/06/09    Relevance Score: 90%

Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma
Oncology (Karger), 11/17/09    Relevance Score: 89%

Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09    Relevance Score: 88%

Today in Head and Neck...keeping you current

Secondary surgery in paediatric facial paralysis reanimation
Journal of Plastic, Reconstructive & Aesthetic Surgery, 12/18/09

Dizziness and vertigo in an older population: the Blue Mountains prospective cross-sectional study
Clinical Otolaryngology, 12/18/09

When will I see you again? Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients
Clinical Otolaryngology, 12/18/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address